Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Bone Marrow Transplant ; 52(4): 580-587, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27991894

ABSTRACT

We hypothesized that IV busulfan (Bu) dosing could be safely intensified through pharmacokinetic (PK-) dose guidance to minimize the inter-patient variability in systemic exposure (SE) associated with body-sized dosing, and that this should improve outcome of AML/MDS patients undergoing allogeneic stem cell transplantation. To test this hypothesis, we treated 218 patients (median age 50.7 years, male/female 50/50%) with fludarabine 40 mg/m2 once daily x4, each dose followed by IV Bu, randomized to 130 mg/m2 (N=107) or PK-guided to average daily SE, AUC of 6000 µM min (N=111), stratified for remission status and allo-grafting from HLA-matched donors. Toxicity and GvHD rates in the groups were similar; the risk of relapse or treatment-related mortality remained higher in the fixed-dose group throughout the 80-month observation period. Further, PK-guidance yielded safer disease control, leading to improved overall and PFS, most prominently in MDS patients and in AML patients not in remission at allogeneic stem cell transplantation. We conclude that AML/MDS patients receiving pretransplant conditioning treatment with our 4-day regimen may benefit significantly from PK-guided Bu dosing. This could be considered an alternative to fixed-dose delivery since it provides the benefit of precise dose delivery to a predetermined SE without increasing risk(s) of serious toxicity and/or GvHD.


Subject(s)
Busulfan/administration & dosage , Drug Monitoring/methods , Leukemia, Myeloid, Acute/therapy , Myelodysplastic Syndromes/therapy , Transplantation Conditioning/methods , Transplantation, Homologous/methods , Vidarabine/analogs & derivatives , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/toxicity , Busulfan/pharmacokinetics , Busulfan/toxicity , Female , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cell Transplantation/mortality , Humans , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Myelodysplastic Syndromes/mortality , Recurrence , Survival Analysis , Transplantation Conditioning/mortality , Transplantation, Homologous/mortality , Treatment Outcome , Vidarabine/administration & dosage
2.
Anticancer Res ; 21(3B): 1697-704, 2001.
Article in English | MEDLINE | ID: mdl-11497249

ABSTRACT

BACKGROUND: The urokinase plasminogen activator (uPA) system has been implicated in cellular invasiveness of tumor cells and immune cells. Herein we provide evidence for the production by natural killer (NK) cells of both uPA and its receptor (uPAR). MATERIALS AND METHODS: Western blot analysis, RTPCR, casein/plasminogen zymography, and fluorescence microscopy were employed to detect uPA and uPAR on NK cells. NK cell invasiveness was examined using Matrigel invasion assays. RESULTS: NK cell uPA appeared at its characteristic molecular weights, is enzymatically active in casein/plasminogen zymography, and is recognized by monoclonal antibodies. uPAR was detected by RTPCR and fluorescence microscopy. Matrigel invasion assays demonstrated an active role of uPA in NK cell invasion. CONCLUSION: The uPA system contributes to extracellular matrix (ECM) degradation by NK cells, which may be essential for NK cell accumulation into metastases, and may be prerequisite for their killing of tumor cells following NK cell adoptive transfer.


Subject(s)
Extracellular Matrix/metabolism , Killer Cells, Natural/metabolism , Receptors, Cell Surface/metabolism , Urokinase-Type Plasminogen Activator/metabolism , 3T3 Cells , Animals , Antibodies, Monoclonal/metabolism , Aprotinin/metabolism , Blotting, Western , Caseins/metabolism , Cell Membrane/metabolism , Cell Movement , Collagen/metabolism , Drug Combinations , Humans , Laminin/metabolism , Mice , Microscopy, Fluorescence , Neoplasm Invasiveness , Phenotype , Phosphatidylinositol Diacylglycerol-Lyase , Plasminogen/metabolism , Proteoglycans/metabolism , RNA, Messenger/metabolism , Receptors, Urokinase Plasminogen Activator , Reverse Transcriptase Polymerase Chain Reaction , Type C Phospholipases/pharmacology , U937 Cells
3.
In Vivo ; 14(5): 565-70, 2000.
Article in English | MEDLINE | ID: mdl-11125540

ABSTRACT

We have previously investigated the role of the urokinase plasminogen activator (uPA) system in NK cell invasion. We have also studied NK cell-derived matrix metalloproteinases (MMPs) in extracellular matrix (ECM) degradation. We now report that both enzyme systems cooperate in NK cell invasion. Zymographic analyses detected uPA in RNK-16 cell conditioned media (CM) with the same molecular weights as the uPA we have previously shown to be associated with the rat NK cell urokinase plasminogen activator receptor. The combination of aprotinin, an inhibitor of plasmin, and Batimastat (BB94), an inhibitor of MMPs, in Matrigel invasion assays showed a more potent inhibitory effect on NK cell invasion than either inhibitor alone. Finally, a down regulation of uPA mRNA was noted following RNK-16 stimulation with collagen IV, fibronectin, and laminin.


Subject(s)
Killer Cells, Natural/enzymology , Lymphocytes, Tumor-Infiltrating/metabolism , Matrix Metalloproteinases/metabolism , Phenylalanine/analogs & derivatives , Urokinase-Type Plasminogen Activator/metabolism , Animals , Aprotinin/pharmacology , Collagen/pharmacology , Culture Media, Conditioned/chemistry , Down-Regulation , Fibronectins/pharmacology , Humans , Killer Cells, Natural/drug effects , Laminin/pharmacology , Lymphocytes, Tumor-Infiltrating/drug effects , Phenylalanine/pharmacology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Rats , Reverse Transcriptase Polymerase Chain Reaction , Thiophenes/pharmacology , Tumor Cells, Cultured , Urokinase-Type Plasminogen Activator/genetics
4.
In Vivo ; 14(1): 101-4, 2000.
Article in English | MEDLINE | ID: mdl-10757065

ABSTRACT

Adoptively transferred IL-2 activated NK (A-NK) cells selectively accumulate within tumor metastases which recommends them as vehicles for locoregional drug delivery. Zyn-Linkers are membrane-binding lipophilic dyes which can be coupled by a variety of conjugation chemistries to therapeutic agents. We have previously demonstrated that A-NK cells labeled with PKH26 are able to accumulate within established B16 melanoma pulmonary metastases by 16 h at a concentration of over 600 cells/mm2 of tumor tissue (Basse et al. J. Exp. Med. 174: 479 1991). Zyn-205 is a prodrug in which doxorubicin is attached to a similar Zyn-Linker through an acid-sensitive bond. We have optimized the ex vivo labeling conditions and found that a 10 min incubation with 25 microM Zyn-205 results in the uptake of over 10(8) drug molecules per cell with no effect on either cell viability or cytolytic activity up to 24 h after labeling. Given these parameters, the amount of drug which may be carried to and concentrated in metastatic lesions represents a local concentration of approximately 15 microM. In addition, A-NK cells carrying Zyn-Linked doxorubicin at an equivalent dose of 25 micrograms/kg was therapeutically comparable to a systemic dose of 8 mg/kg (320x more) in the 3LL model of experimental metastasis. These data indicate that A-NK cells bearing Zyn-Linked chemotherapeutic agents represent a unique and feasible method to target chemotherapeutic agents to cancer metastases and that therapeutic doses can be attained without unwanted systemic exposure.


Subject(s)
Antineoplastic Agents/administration & dosage , Doxorubicin/administration & dosage , Drug Delivery Systems , Interleukin-2/pharmacology , Killer Cells, Lymphokine-Activated/immunology , Animals , Antineoplastic Agents/chemistry , Cell Count/drug effects , Doxorubicin/chemistry , Fluorescent Dyes/chemistry , Immunotherapy, Adoptive , Killer Cells, Lymphokine-Activated/cytology , Killer Cells, Lymphokine-Activated/drug effects , Lung Neoplasms/drug therapy , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Melanoma, Experimental/drug therapy , Melanoma, Experimental/immunology , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Survival Analysis , Treatment Outcome , Tumor Cells, Cultured
5.
Br J Urol ; 82(5): 698-703, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9839586

ABSTRACT

OBJECTIVES: To report the initial experience of hypospadias repair using an axially vascularized meatal-based skin flap. PATIENTS AND METHODS: Twenty-six children aged 2-5.5 years with subcoronal hypospadias underwent the procedure: three were circumcised and three had recurrent hypospadias. The neourethra was constructed using a meatal-based flap extending obliquely from the hypospadiac orifice towards the prepuce or its remnants. The flap was supplied axially by the ventrolateral branch of the superficial external pudendal artery. The vascular pedicle was dissected and mobilized to allow tensionless reflection of the flap ventrally to be sutured to the urethral plate. RESULTS: Functional and cosmetic success was achieved in 25 of the patients (96%). Haematoma and disruption of the flap occurred in one patient, who underwent re-operation, and slight and insignificant meatal retraction occurred in another child. CONCLUSIONS: The procedure confirmed the technical feasibility of creating an axially vascularized meatal-based flap. The oblique orientation of the flap permits it to be obtained from well-developed skin. Continuity of the oblique flap with the urethral plate reduces the total length of suture lines and minimizes the possibility of fistula formation.


Subject(s)
Hypospadias/surgery , Surgical Flaps/blood supply , Child, Preschool , Follow-Up Studies , Humans , Male , Recurrence , Surgery, Plastic/methods , Suture Techniques , Urologic Surgical Procedures, Male
SELECTION OF CITATIONS
SEARCH DETAIL
...